Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevasiranib
- Development stage
- Phase 2
- Lead developer
- OPKO Health
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal, Ophthalmic
01
Overview
Bevasiranib is a small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor A (VEGF-A), a protein that promotes blood vessel growth. By inhibiting VEGF-A expression, bevasiranib aims to slow the growth and leakage of abnormal blood vessels associated with conditions such as wet age-related macular degeneration and diabetic macular edema. The drug is administered via intravitreal injection directly into the eye. It was developed by OPKO Health and represents one of the first RNA interference-based therapies to reach advanced clinical trials for ophthalmic diseases[1][3][8].
- Other names
- bevasiranibumBevasiranib [INN]BEVASIRANIB [WHO-DD]959961-96-7bevasiranib sodiumCand5 sodiumCand-5 sodiumCand 5 sodium
02
Targets
Beyond the preview
Go deeper on bevasiranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevasiranib.